Dupilumab and subcutaneous immunotherapy for the treatment of refractory moderate to severe atopic dermatitis: A preliminary report.

Deng, Sisi; Wang, Huan; Chen, Shuguang; Kong, Minmin; Yang, Xianjie; Song, Zhiqiang; Chen, Qiquan

Deng, Sisi; Wang, Huan; Chen, Shuguang; Kong, Minmin; Yang, Xianjie; Song, Zhiqiang; Chen, Qiquan.

Afiliación

Deng S; Department of Dermatology, Southwest Hospital, Amy Medical University, Chongqing, China.
Wang H; Department of Dermatology, Southwest Hospital, Amy Medical University, Chongqing, China.
Chen S; Department of Dermatology, Southwest Hospital, Amy Medical University, Chongqing, China.
Kong M; Department of Dermatology, Southwest Hospital, Amy Medical University, Chongqing, China.
Yang X; School of Medicine, Chongqing University, Chongqing 400038, China.
Song Z; Department of Dermatology, Southwest Hospital, Amy Medical University, Chongqing, China. Electronic address: drsongzq@hotmail.com.
Chen Q; Department of Dermatology, Southwest Hospital, Amy Medical University, Chongqing, China. Electronic address: chenqq0548@163.com.

Int Immunopharmacol ; 125(Pt A): 111137, 2023 Dec.

Article en En | MEDLINE | ID: mdl-37897946

Asunto(s)

Dermatitis Atópica; Humanos; Estudios Retrospectivos; Dermatitis Atópica/tratamiento farmacológico; Resultado del Tratamiento; Inyecciones Subcutáneas; Desensibilización Inmunológica; Inmunoglobulina E; Índice de Severidad de la Enfermedad; Método Doble Ciego

Palabras clave

Atopic dermatitis; Dupilumab; Subcutaneous immunotherapy

Texto completo

Imprimir

XML

PubMed Links

Buscar en Google

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Dermatitis Atópica Límite: Humans Idioma: En Año: 2023 Tipo del documento: Article

Texto completo

Imprimir

XML

PubMed Links

Buscar en Google

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Dermatitis Atópica Límite: Humans Idioma: En Año: 2023 Tipo del documento: Article